YieldMax MRNA Option Income Strategy ETF

$Moderna(MRNA.US)

POST for 14/9 (Next Episode)

1️⃣ I sold MRNA at this price because the stock had rebounded strongly and I viewed that level as an opportunity to lock in gains while reducing exposure to biotech volatility and uncertainly around future vaccine revenue.

2️⃣ I did not want to add after my last purchase because the investment thesis had not materially improved, and I preferred to wait for clearer evidence of sustainable earning growth.

3️⃣ Looking a few months ahead, the outlook depends on pipeline progress, regulatory updates and commercialisation pressures may keep the stock range bound.

💊$Moderna(MRNA.US)

Breaking: We found a politician day trading a cancer treatment

$XTALPI(02228.HK) On the plane, reading some materials on Moderna, I suddenly feel that maybe Crownpeak's decision to abandon its own pipeline and focus solely on being a platform could be a mistake. This might be a potential concern and point of reflection for the market in its pricing. After all, the business model of a platform approach always lacks certainty. However, interestingly, Crownpeak's role in driving pipeline progress within the ecosystem is positive.

It really puts me in a dilemma.